BrainsWay to Engage Investors at Citi MedTech Conference
Event summary
- BrainsWay management to participate in one-on-one investor meetings at Citi 2026 Unplugged MedTech and Life Sciences Access Day on February 26, 2026.
- Event takes place in New York, NY.
- BrainsWay is a global leader in noninvasive brain stimulation technologies for mental health disorders.
- Company has three FDA-cleared indications for its Deep TMS™ platform technology.
- Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
The big picture
BrainsWay's participation in the Citi conference underscores its strategic focus on engaging with investors to highlight its leadership in noninvasive brain stimulation. The company's three FDA-cleared indications position it strongly in the mental health technology sector, where regulatory approvals and clinical trial outcomes are critical drivers of market valuation. The event provides a platform to discuss its expansion into new therapeutic areas and its commitment to superior science.
What we're watching
- Investor Sentiment
- How BrainsWay's presentations will impact investor perception of its growth prospects and market positioning.
- Regulatory Expansion
- Whether BrainsWay can secure additional FDA clearances for new indications, expanding its market reach.
- Clinical Trials
- The pace at which ongoing clinical trials for various psychiatric, neurological, and addiction disorders will yield results.
Related topics